ARCHIVES

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

Proteomics Promises Ways To Track Response To Therapy

April 25, 2003

U.S. Tobacco Program Loses $505 il. In Loan Principle, Report Finds

January 5, 1990

NCAB Committee Ok’s Recompetition of OD Support Contract

May 22, 1992

FDA Asks Advisory Group To Define Role Of Single-Arm Studies In Four Applications

September 4, 2009

In Brief: William Peters To Leave Duke To Head Michigan Cancer Foundation, Prentis Center

April 7, 1995

Senate Passes Biomedical Research Extension; Could Go to President before Congress Recesses

July 26, 1985